News Details

BRANFORD, Conn.--(BUSINESS WIRE)--Feb. 18, 2025-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^™, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26^th.

Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery.

Scientific Posters Highlighting NGPS Innovation

Beyond the genome: Advancing our understanding of the proteome with Next-Generation Protein Sequencing^™

• Presenter: Meredith Carpenter, Ph.D., Head of Scientific Affairs, Quantum-Si
• Introduces how NGPS offers an integrated understanding of cellular processes by detecting changes at the protein level (such as post-translational modifications, or PTMs) that cannot be captured by genomics data alone.
• February 25^th, Poster 412

Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability

• Presenter: Gloria Sheynkman, Ph.D., Assistant Professor, University of Virginia
• Demonstrates the integration of long-read RNA sequencing to capture transcript isoforms, combined with the benchtop instrument Platinum™ to produce single-molecule peptide sequencing data.
• February 25^th Poster 476

Identifying Protein Binding Partners at the Bench Using Quantum-Si

• Presenter: Winston Timp, Ph.D., Associate Professor, BioMedical Engineering and Molecular Biology and Genetics, Johns Hopkins University
• Demonstrates how NGPS enables direct peptide sequencing to identify protein partners regulated by genomic, epigenomic, or splicing variation, offering a rapid and cost-effective alternative to legacy technologies.
• February 24^th, Poster 465

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218012265/en/

Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com

Source: Quantum-Si Incorporated